Objective： Diffuse large B-cell lymphoma （DLBCL） is a heterogeneous disease. The prognostic factor currently used is not accurate enough to predict the outcomes of patients with DLBCL. The prognostic significance o...Objective： Diffuse large B-cell lymphoma （DLBCL） is a heterogeneous disease. The prognostic factor currently used is not accurate enough to predict the outcomes of patients with DLBCL. The prognostic significance of interim PET/CT in DLBCL remains controversial. The aim of this study is to determine the predictive value of interim 18F-FDG PET/CT after first-line treatment in patients with DLBCL. Methods： Thirty-two patients with DLBCL underwent baseline, interim and post-treatment lSF-FDG PET/CT scans. Imaging results were analyzed for the survival of patients via software SPSS 13.0, retrospectively. Results： Thirty-one of the 32 patients were treated with R-CHOP regimen, and interim 18F-FDG PET/CT of 24 patients was performed after 2 cycles of treatment. After a median follow-up period of 16.7 months, the 2-year progression-free survival （PFS） rates were significantly different between the groups above and below SUVmax CUt-Off value of 2.5 （P=0.039）. No significant differences were found in the 2-year PFS rates if SUVm, cut-offvalues were set as 2.0 and 3.0, respectively （P=0.360; P=0.113）. Conclusions： Interim PET/CT could predict the prognosis of DLBCL patients with the SUVmax cut-off value of 2.5, but more clinical data should be concluded to confirm this conclusion.展开更多
目的探讨人新基因溶酶体相关4次跨膜蛋白质B(lysosome-associated protein transmembrane 4 beta,LAPTM4B)多态性与淋巴瘤易感性的关系。方法以病例-对照研究的方法,基于特异性引物的PCR对350例正常人和166例胃癌患者进行LAPTM4B基因分...目的探讨人新基因溶酶体相关4次跨膜蛋白质B(lysosome-associated protein transmembrane 4 beta,LAPTM4B)多态性与淋巴瘤易感性的关系。方法以病例-对照研究的方法,基于特异性引物的PCR对350例正常人和166例胃癌患者进行LAPTM4B基因分型,用χ2检验检测淋巴瘤组和对照组基因型频率和其他参数的分布。结果淋巴瘤组中LAPTM4B基因的*2等位基因的频率为34.94%,较对照组(24.14%)显著增高(P<0.001)。基因型分布在淋巴瘤组与对照组间差异有统计学意义。*1/2和*2/2基因携带者患淋巴瘤的危险性分别是*1/1的1.475倍(95%CI:0.994-2.189)与3.532倍(95%CI:1.802-6.923)。*2等位基因携带者患淋巴瘤的危险性是*1等位基因的1.710倍(95%CI:1.287-2.271)。LAPTM4B基因型分布与患者年龄、性别、病理类型、临床分期、HBV感染、乳酸脱氢酶(LDH)、β2-微球蛋白(β2-MG)以及有无全身症状等参数无明显关系。结论LAPTM4B基因多态性与淋巴瘤易感性相关,*2等位基因可能是淋巴瘤发生的危险因素。展开更多
目的:探讨STAT3在艾滋病相关弥漫性大B细胞淋巴瘤(ADIS/HIV-related diffuse large B-cell l y m p h o m a,H I V-D L B CL)中的表达及意义。方法:收集2 1例H I V-D L B CL组织标本作为实验组。对照组15例标本,分别为6例HIV阴性的DLBCL...目的:探讨STAT3在艾滋病相关弥漫性大B细胞淋巴瘤(ADIS/HIV-related diffuse large B-cell l y m p h o m a,H I V-D L B CL)中的表达及意义。方法:收集2 1例H I V-D L B CL组织标本作为实验组。对照组15例标本,分别为6例HIV阴性的DLBCL(non-HIV-DLBCL)、4例HIV阳性淋巴结反应性增生(HIV-reactive hyperplasia,HIV-RH)、5例HIV阴性淋巴结反应性增生(non-HIV-RH)。采用免疫组化检测各样本中STAT3的表达情况,并结合患者的临床病理因素分析。结果:HIV-DLBCL中STAT3总阳性表达率为76.19%,以胞核表达为主占81.25%;non-HIV-DLBCL中STAT3总阳性表达率为66.67%,以胞核表达为主占50%;两组总阳性率及核阳性率差异无统计学意义(P>0.05)。H I V-R H和n o n-H I V-R H中,STAT 3仅表达于淋巴滤泡细胞;H I V-D L B CL中STAT 3表达率与良性病变组具有显著性差异(P<0.05)。STAT3在non-GCB型HIV-DLBCL中的表达明显高于GCB型HIVDLBCL(P<0.01),与性别、年龄、发病部位及临床分期等因素无关(P>0.05)。结论:STAT3在HIVD L B CL和n o n-H I V-D L B CL中均呈高表达,且以核表达为主,提示STAT 3过表达与D L B CL的发生有关;STAT3表达与HIV-DLBCL的免疫表型有关,因不同免疫表型DLBCL的预后存在差异,提示STAT3可能是HIV-DLBCL的潜在预后标志物。展开更多
目的 探讨Bcl-2和Bcl-6在弥漫性大B细胞淋巴瘤（diffuse large B cell lymphoma,DLBCL）中的表达及意义.方法 收集46例2004年1月～2014年6月经行淋巴结活检初诊的DLBCL病例及病理资料,采用免疫组化方法检测DLBCL患者组织中Bcl-2及Bcl-6...目的 探讨Bcl-2和Bcl-6在弥漫性大B细胞淋巴瘤（diffuse large B cell lymphoma,DLBCL）中的表达及意义.方法 收集46例2004年1月～2014年6月经行淋巴结活检初诊的DLBCL病例及病理资料,采用免疫组化方法检测DLBCL患者组织中Bcl-2及Bcl-6的表达情况,分析二者免疫组化指标与DLBCL临床特征及预后的关系.结果 ①46例DLBCL中行Bcl-2检测,阳性表达率为63.04％（29/46例）,行Bcl-6检测,阳性表达率为73.91％（34/46例）.②Bcl-2和Bcl-6表达与患者性别、年龄、有无全身症状、有无结外侵犯及PS评分无关（P＞0.05）,而与临床分期和IPI评分呈正相关（P＜0.05）.③Bcl-2和Bcl-6表达阳性患者其近期疗效和预后（总体生存期和无进展生存期）显著低于阴性患者,组间差异有统计学意义（P＜0.05）.结论 Bcl-2和Bcl-6阳性表达提示近期疗效与预后不佳,其水平可被视为独立的DLBCL分析因素,对患者治疗过程中病情发展的预测、个体化治疗策略的制定有重要意义.展开更多
文摘Objective： Diffuse large B-cell lymphoma （DLBCL） is a heterogeneous disease. The prognostic factor currently used is not accurate enough to predict the outcomes of patients with DLBCL. The prognostic significance of interim PET/CT in DLBCL remains controversial. The aim of this study is to determine the predictive value of interim 18F-FDG PET/CT after first-line treatment in patients with DLBCL. Methods： Thirty-two patients with DLBCL underwent baseline, interim and post-treatment lSF-FDG PET/CT scans. Imaging results were analyzed for the survival of patients via software SPSS 13.0, retrospectively. Results： Thirty-one of the 32 patients were treated with R-CHOP regimen, and interim 18F-FDG PET/CT of 24 patients was performed after 2 cycles of treatment. After a median follow-up period of 16.7 months, the 2-year progression-free survival （PFS） rates were significantly different between the groups above and below SUVmax CUt-Off value of 2.5 （P=0.039）. No significant differences were found in the 2-year PFS rates if SUVm, cut-offvalues were set as 2.0 and 3.0, respectively （P=0.360; P=0.113）. Conclusions： Interim PET/CT could predict the prognosis of DLBCL patients with the SUVmax cut-off value of 2.5, but more clinical data should be concluded to confirm this conclusion.
文摘目的探讨人新基因溶酶体相关4次跨膜蛋白质B(lysosome-associated protein transmembrane 4 beta,LAPTM4B)多态性与淋巴瘤易感性的关系。方法以病例-对照研究的方法,基于特异性引物的PCR对350例正常人和166例胃癌患者进行LAPTM4B基因分型,用χ2检验检测淋巴瘤组和对照组基因型频率和其他参数的分布。结果淋巴瘤组中LAPTM4B基因的*2等位基因的频率为34.94%,较对照组(24.14%)显著增高(P<0.001)。基因型分布在淋巴瘤组与对照组间差异有统计学意义。*1/2和*2/2基因携带者患淋巴瘤的危险性分别是*1/1的1.475倍(95%CI:0.994-2.189)与3.532倍(95%CI:1.802-6.923)。*2等位基因携带者患淋巴瘤的危险性是*1等位基因的1.710倍(95%CI:1.287-2.271)。LAPTM4B基因型分布与患者年龄、性别、病理类型、临床分期、HBV感染、乳酸脱氢酶(LDH)、β2-微球蛋白(β2-MG)以及有无全身症状等参数无明显关系。结论LAPTM4B基因多态性与淋巴瘤易感性相关,*2等位基因可能是淋巴瘤发生的危险因素。
文摘目的:探讨STAT3在艾滋病相关弥漫性大B细胞淋巴瘤(ADIS/HIV-related diffuse large B-cell l y m p h o m a,H I V-D L B CL)中的表达及意义。方法:收集2 1例H I V-D L B CL组织标本作为实验组。对照组15例标本,分别为6例HIV阴性的DLBCL(non-HIV-DLBCL)、4例HIV阳性淋巴结反应性增生(HIV-reactive hyperplasia,HIV-RH)、5例HIV阴性淋巴结反应性增生(non-HIV-RH)。采用免疫组化检测各样本中STAT3的表达情况,并结合患者的临床病理因素分析。结果:HIV-DLBCL中STAT3总阳性表达率为76.19%,以胞核表达为主占81.25%;non-HIV-DLBCL中STAT3总阳性表达率为66.67%,以胞核表达为主占50%;两组总阳性率及核阳性率差异无统计学意义(P>0.05)。H I V-R H和n o n-H I V-R H中,STAT 3仅表达于淋巴滤泡细胞;H I V-D L B CL中STAT 3表达率与良性病变组具有显著性差异(P<0.05)。STAT3在non-GCB型HIV-DLBCL中的表达明显高于GCB型HIVDLBCL(P<0.01),与性别、年龄、发病部位及临床分期等因素无关(P>0.05)。结论:STAT3在HIVD L B CL和n o n-H I V-D L B CL中均呈高表达,且以核表达为主,提示STAT 3过表达与D L B CL的发生有关;STAT3表达与HIV-DLBCL的免疫表型有关,因不同免疫表型DLBCL的预后存在差异,提示STAT3可能是HIV-DLBCL的潜在预后标志物。
文摘目的 探讨Bcl-2和Bcl-6在弥漫性大B细胞淋巴瘤（diffuse large B cell lymphoma,DLBCL）中的表达及意义.方法 收集46例2004年1月～2014年6月经行淋巴结活检初诊的DLBCL病例及病理资料,采用免疫组化方法检测DLBCL患者组织中Bcl-2及Bcl-6的表达情况,分析二者免疫组化指标与DLBCL临床特征及预后的关系.结果 ①46例DLBCL中行Bcl-2检测,阳性表达率为63.04％（29/46例）,行Bcl-6检测,阳性表达率为73.91％（34/46例）.②Bcl-2和Bcl-6表达与患者性别、年龄、有无全身症状、有无结外侵犯及PS评分无关（P＞0.05）,而与临床分期和IPI评分呈正相关（P＜0.05）.③Bcl-2和Bcl-6表达阳性患者其近期疗效和预后（总体生存期和无进展生存期）显著低于阴性患者,组间差异有统计学意义（P＜0.05）.结论 Bcl-2和Bcl-6阳性表达提示近期疗效与预后不佳,其水平可被视为独立的DLBCL分析因素,对患者治疗过程中病情发展的预测、个体化治疗策略的制定有重要意义.
